Nadine Dragin, a researcher from an Inserm/UPMC/CNRS/AIM team codirected by Sonia Berrih-Aknin and Rozen le Panse at the Institute of Myology, based at Pitié-Salpêtrière Hospital, AP-HP, has demonstrated the central role of AIRE, a key factor in immune tolerance, in the unequal impact of autoimmune diseases on men and women. This work, published in The Journal of Clinical Investigation on 1 April 2016, was funded by AFM-Téléthon.
Asthma, a chronic inflammatory disease, usually results from the combination of a genetic predisposition and environmental factors such as allergens (moulds, house dust mites and pollen), tobacco smoke or air pollution. During an episode, the lining of the bronchi swells, causing their diameter to become narrower, and leading to breathing difficulties, accompanied by wheezing.
A research team from Paris Descartes University, Inserm and Sainte-Anne Hospital, led by Professor Marie-Odile Krebs, has demonstrated that epigenetic modifications accompany the onset of a psychotic episode in a cohort of young at-risk people aged 15–25 years. These modifications compromise systems for responding to oxidative stress and inflammation. Through this new work, the researchers have shed new light on this disease, for which the main biological explanation, before now, was based on disruption of dopamine secretion in the brain.
The European Commission is legally required to provide criteria identifying Endocrine Disrupting Chemicals (EDCs), a process that has been blocked for almost three years, allegedly because of a lack of scientific consensus and because an impact assessment study was deemed necessary. Now, a group of 7 independent researchers from universities and research institutions from Europe and the United States* show how little controversy there is around the definition of EDCs, and that the simple logic used for the identification and regulation of carcinogens can be used for EDCs. The study is published this Monday as a commentary in the scientific journal Environmental Health Perspectives.
In the last two years, nearly 2 million people have been infected with the Zika virus in Latin America and the Caribbean. At the end of 2015, REACTing and members of the Aviesan alliance immediately became involved, particularly Inserm, Institut Pasteur, the Institute for Development Research (IRD), the French Blood Transfusion Service and the associated university hospitals. Initial contact was made with Brazilian researchers from Fiocruz in November 2015. The international Zika Summit conference, taking place at Institute Pasteur on the 25 and 26 April 2016, will review ongoing research projects: